<DOC>
	<DOCNO>NCT00189748</DOCNO>
	<brief_summary>To assess safety efficacy patient MR4 therapy GVHD prophylaxis study eligible administration 100 day post transplant ( 1 year )</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Tacrolimus New Oral Formulation ( MR4 ) BMT Patients-Extension-</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patient enrol GVHD prophylaxis study . Patient fully inform . The patient eligible administration 100 day post transplant investigator 's judgement .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Bone Marrow Transplantation</keyword>
	<keyword>Graft versus Host Disease</keyword>
</DOC>